sagopilone
Small moleculeexperimental
Clinical trial activity
14 trials · 8 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
13
Phase 3
0
Phase 4
0
Earliest trial started Aug 1, 2005 (NCT00160069)
Timeline
Indications
Studied for
- Brain Neoplasms · Phase 2
- Breast Neoplasms · Phase 2
- Carcinoma, Non-Small-Cell Lung · Phase 2
- Carcinoma, Small Cell · Phase 1/Phase 2
- Central Nervous System Diseases · Phase 2
- Glioblastoma · Phase 2
- Melanoma · Phase 2
- Neoplasms · Phase 1
- Ovarian Neoplasms · Phase 2
- Prostatic Neoplasms · Phase 2
- Small Cell Lung Carcinoma · Phase 2
Mechanism of action
- TubulinSTABILISER
Tubulin stabiliser
- Tubulin beta-4B chain (TUBB4B) ↗
- Tubulin beta-1 chain (TUBB1) ↗
- Tubulin alpha-3C chain (TUBA3C) ↗
- Tubulin alpha-4A chain (TUBA4A) ↗
- Tubulin beta-3 chain (TUBB3) ↗
- Tubulin alpha-1A chain (TUBA1A) ↗
- Tubulin beta-4A chain (TUBB4A) ↗
- Tubulin beta-8 chain (TUBB8) ↗
- Tubulin beta chain (TUBB) ↗
- Tubulin alpha-1B chain (TUBA1B) ↗
- Tubulin alpha-1C chain (TUBA1C) ↗
- Tubulin alpha-3E chain (TUBA3E) ↗
- Tubulin beta-2A chain (TUBB2A) ↗
- Tubulin beta-2B chain (TUBB2B) ↗
- Tubulin beta-6 chain (TUBB6) ↗
Chemistry & pharmacology
Loading structure…
SMILES
C=CC[C@H]1C(=O)C(C)(C)[C@@H](O)CC(=O)O[C@H](c2ccc3sc(C)nc3c2)C[C@@H]2O[C@]2(C)CCC[C@H](C)[C@@H]1O- Mol. weight
- 543.73 g/mol
- Lipinski Ro5
- 2 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL2304041 ↗
Also known as
- bay-86-5302
- de-03757
- de-03757
- de-03757
- epo-477
- sagopilone
- sagopilone
- sagopilone
- sagopilone
- sagopilone
- sh-y-03757
- sh-y03757a
- zk219477
- zk-219477
- zk-219477
- zk-219477
- zk-epo
- zk-epothilone
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00751205 | Phase 2 | Aug 1, 2008 | Bayer |
| NCT00496379 | Phase 2 | Jul 1, 2007 | Bayer, Breast Cancer Research Foundation, Harvard University |
| NCT00598507 | Phase 2 | May 1, 2007 | Bayer, University of South Florida |
| NCT00432302 | Phase 1 | Jan 1, 2007 | Bayer |
| NCT00424060 | Phase 2 | Dec 1, 2006 | European Organisation for Research and Treatment of Cancer, University of Lausanne |
| NCT00325351 | Phase 2 | Aug 1, 2006 | Bayer |
| NCT00350051 | Phase 2 | Aug 1, 2006 | Bayer |
| NCT00359359 | Phase 1/Phase 2 (Phase 2) | Jul 1, 2006 | Bayer |
| NCT00397072 | Phase 2 | Jun 1, 2006 | Carlo Besta Neurological Institute, Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta |
| NCT00313248 | Phase 2 | Apr 1, 2006 | Bayer |
| NCT00299390 | Phase 2 | Apr 1, 2006 | Bayer |
| NCT00288249 | Phase 2 | Dec 1, 2005 | Bayer |
| NCT00246688 | Phase 2 | Nov 1, 2005 | Bayer |
| NCT00160069 | Phase 2 | Aug 1, 2005 | Bayer |
Showing 14 of 14 trials
Page 1 / 1
Organizations
Research & Development (8)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Bayer | For profit | 12 | 10 | 2 | 2005 |
| Breast Cancer Research Foundation | Academic/Hospital | 1 | 0 | 1 | 2007 |
| Carlo Besta Neurological Institute | Academic/Hospital | 1 | 0 | 1 | 2006 |
| European Organisation for Research and Treatment of Cancer | Academic/Hospital | 1 | 1 | 1 | 2006 |
| Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta | Academic/Hospital | 1 | 1 | 1 | 2006 |
| Harvard University | Academic/Hospital | 1 | 1 | 1 | 2007 |
| University of Lausanne | Academic/Hospital | 1 | 0 | 1 | 2006 |
| University of South Florida | Academic/Hospital | 1 | 1 | 1 | 2007 |
8 organizations
Page 1 / 1